Quarterly report · Q1
7446.TEDINET S100ST6L
Period2023-10-01 → 2023-12-31
Filed2024-02-13
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 31
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥8.3bn | 2023-10-01 → 2023-12-31 | Cons. | Net sales |
| Revenue | ¥35.1bn | 2022-10-01 → 2023-09-30 | Cons. | Net sales (5-year summary) |
| Revenue | ¥9.4bn | 2022-10-01 → 2022-12-31 | Cons. | Net sales |
| Operating income | ¥58m | 2023-10-01 → 2023-12-31 | Cons. | Operating income |
| Operating income | ¥254m | 2022-10-01 → 2022-12-31 | Cons. | Operating income |
| Ordinary income | ¥78m | 2023-10-01 → 2023-12-31 | Cons. | Ordinary income |
| Ordinary income | ¥808m | 2022-10-01 → 2023-09-30 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥271m | 2022-10-01 → 2022-12-31 | Cons. | Ordinary income |
| Profit before tax | ¥90m | 2023-10-01 → 2023-12-31 | Cons. | Income before income taxes |
| Profit before tax | ¥271m | 2022-10-01 → 2022-12-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥53m | 2023-10-01 → 2023-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥556m | 2022-10-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥182m | 2022-10-01 → 2022-12-31 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥53m | 2023-10-01 → 2023-12-31 | Cons. | Profit loss |
| Net income | ¥187m | 2022-10-01 → 2022-12-31 | Cons. | Profit loss |
| Total assets | ¥19.7bn | at 2023-12-31 | Cons. | Assets |
| Total assets | ¥18.9bn | at 2023-09-30 | Cons. | Assets |
| Total assets | ¥19.2bn | at 2022-12-31 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥12.4bn | at 2023-12-31 | Cons. | Liabilities |
| Total liabilities | ¥11.7bn | at 2023-09-30 | Cons. | Liabilities |
| Net assets / equity | ¥7.3bn | at 2023-12-31 | Cons. | Net assets |
| Net assets / equity | ¥7.3bn | at 2023-09-30 | Cons. | Net assets |
| Net assets / equity | ¥6.7bn | at 2022-12-31 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.3bn | at 2023-12-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥2.2bn | at 2023-09-30 | Cons. | Cash and deposits |
| EPS (basic) | ¥59.34 | 2023-10-01 → 2023-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥617.29 | 2022-10-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥202.31 | 2022-10-01 → 2022-12-31 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 36.5% | at 2023-12-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 34.7% | at 2022-12-31 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 16
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q1r_E02810-000Academia Life Science Sales Groupreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥518m |
| jpcrp040300-q1r_E02810-000Academia Life Science Sales Groupreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥518m |
| jpcrp040300-q1r_E02810-000Industry Sales Groupreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥4.2bn |
| jpcrp040300-q1r_E02810-000Industry Sales Groupreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥4.2bn |
| jpcrp040300-q1r_E02810-000Medical Sales Groupreportable segment | revenue | 2023-10-01 → 2023-12-31 | ¥3.6bn |
| jpcrp040300-q1r_E02810-000Medical Sales Groupreportable segment | revenue external | 2023-10-01 → 2023-12-31 | ¥3.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-10-01 → 2023-12-31 | ¥8.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-10-01 → 2023-12-31 | ¥8.3bn |
| jpcrp040300-q1r_E02810-000Academia Life Science Sales Groupreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥552m |
| jpcrp040300-q1r_E02810-000Academia Life Science Sales Groupreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥552m |
| jpcrp040300-q1r_E02810-000Industry Sales Groupreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥4.6bn |
| jpcrp040300-q1r_E02810-000Industry Sales Groupreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥4.6bn |
| jpcrp040300-q1r_E02810-000Medical Sales Groupreportable segment | revenue | 2022-10-01 → 2022-12-31 | ¥4.3bn |
| jpcrp040300-q1r_E02810-000Medical Sales Groupreportable segment | revenue external | 2022-10-01 → 2022-12-31 | ¥4.3bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-10-01 → 2022-12-31 | ¥9.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-10-01 → 2022-12-31 | ¥9.4bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 365
| Item | Context | Value | Unit |
|---|---|---|---|
| Notes regarding dividend (text) | Prior1YTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | Prior1YTDDuration | Text · Plus | |
| Notes regarding dividend (text) | CurrentYTDDuration | Text · Plus | |
| Notes when there is significant changes in amounts of equity (text) | CurrentYTDDuration | Text · Plus | |
| Notes segment information etc quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | Prior1YTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | Prior1YTDDuration | Text · Plus | |
| Footnotes regarding segment information table (text) | CurrentYTDDuration | Text · Plus | |
| Information about impairment loss of non current assets or goodwill etc for each reportable segment (text) | CurrentYTDDuration | Text · Plus | |
| Disclosure of changes etc in reportable segments (text) | CurrentYTDDuration | Text · Plus | |
| Notes revenue recognition quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes per share information quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Notes significant events after reporting period quarterly consolidated financial statements (text) | CurrentYTDDuration | Text · Plus | |
| Other information consolidated financial statements etc (text) | CurrentYTDDuration | Text · Plus | |
| Information about company which provides guarantee to reporting company (text) | FilingDateInstant | Text · Plus |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 12 of 12 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |